TDOC vs. HIMS, ARDX, CNMD, SANA, APGE, ASTH, RCKT, MRVI, KROS, and CGON
Should you be buying Teladoc Health stock or one of its competitors? The main competitors of Teladoc Health include Hims & Hers Health (HIMS), Ardelyx (ARDX), CONMED (CNMD), Sana Biotechnology (SANA), Apogee Therapeutics (APGE), Astrana Health (ASTH), Rocket Pharmaceuticals (RCKT), Maravai LifeSciences (MRVI), Keros Therapeutics (KROS), and CG Oncology (CGON). These companies are all part of the "medical" sector.
Teladoc Health (NYSE:TDOC) and Hims & Hers Health (NYSE:HIMS) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, media sentiment, analyst recommendations, risk and community ranking.
In the previous week, Hims & Hers Health had 53 more articles in the media than Teladoc Health. MarketBeat recorded 59 mentions for Hims & Hers Health and 6 mentions for Teladoc Health. Hims & Hers Health's average media sentiment score of 0.57 beat Teladoc Health's score of 0.34 indicating that Hims & Hers Health is being referred to more favorably in the news media.
Teladoc Health received 643 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 63.47% of users gave Teladoc Health an outperform vote while only 33.33% of users gave Hims & Hers Health an outperform vote.
Hims & Hers Health has lower revenue, but higher earnings than Teladoc Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than Teladoc Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health has a net margin of -0.24% compared to Teladoc Health's net margin of -8.90%. Hims & Hers Health's return on equity of -0.70% beat Teladoc Health's return on equity.
Teladoc Health has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Hims & Hers Health has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
76.8% of Teladoc Health shares are held by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are held by institutional investors. 1.0% of Teladoc Health shares are held by insiders. Comparatively, 31.6% of Hims & Hers Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Teladoc Health currently has a consensus price target of $18.73, indicating a potential upside of 56.76%. Hims & Hers Health has a consensus price target of $15.08, indicating a potential upside of 22.68%. Given Teladoc Health's higher probable upside, equities research analysts clearly believe Teladoc Health is more favorable than Hims & Hers Health.
Summary
Hims & Hers Health beats Teladoc Health on 11 of the 17 factors compared between the two stocks.
Get Teladoc Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for TDOC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TDOC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Teladoc Health Competitors List
Related Companies and Tools
